APA (7th ed.) Citation

ER, L., CPL, H., HM, C., IWC, W., KFK, F., SLY, C., . . . GCF, C. (2026). End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy-Modified N7 Regimen with Dinutuximab Beta. Cancers, 18(6), . https://doi.org/10.3390/cancers18061028

Chicago Style (17th ed.) Citation

ER, Lu, et al. "End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy-Modified N7 Regimen with Dinutuximab Beta." Cancers 18, no. 6 (2026). https://doi.org/10.3390/cancers18061028.

MLA (9th ed.) Citation

ER, Lu, et al. "End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy-Modified N7 Regimen with Dinutuximab Beta." Cancers, vol. 18, no. 6, 2026, https://doi.org/10.3390/cancers18061028.